Wasatch Advisors Inc Harrow Health, Inc. Transaction History

Wasatch Advisors Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 18, 2024	BUY	$9.3 - $13.23 $796,080 - $1.13 Million	85,600 Added 28.29%	388,132 $5.13 Million
Q4 2023 Feb 14, 2024	SELL	$8.1 - $16.36 $1.21 Million - $2.44 Million	-149,150 Reduced 33.02%	302,532 $3.39 Million
Q3 2023 Nov 14, 2023	BUY	$14.03 - $22.08 $1.53 Million - $2.4 Million	108,783 Added 31.72%	451,682 $6.49 Million
Q2 2023 Aug 07, 2023	SELL	$17.37 - $28.08 $134,878 - $218,041	-7,765 Reduced 2.21%	342,899 $6.53 Million
Q1 2023 May 12, 2023	SELL	$13.84 - $21.46 $5.58 Million - $8.65 Million	-403,131 Reduced 53.48%	350,664 $7.42 Million
Q4 2022 Feb 14, 2023	SELL	$10.28 - $14.78 $1.81 Million - $2.6 Million	-175,611 Reduced 18.89%	753,795 $11.1 Million
Q2 2022 Aug 12, 2022	BUY	$5.75 - $7.74 $1.09 Million - $1.47 Million	189,302 Added 25.58%	929,406 $6.77 Million
Q1 2022 May 13, 2022	BUY	$6.77 - $8.66 $506,395 - $647,768	74,800 Added 11.24%	740,104 $5.05 Million
Q4 2021 Feb 15, 2022	BUY	$8.5 - $12.0 $826,514 - $1.17 Million	97,237 Added 17.12%	665,304 $5.75 Million
Q3 2021 Nov 12, 2021	BUY	$6.99 - $10.6 $3.97 Million - $6.02 Million	568,067 New	568,067 $5.16 Million

179

21.3M

845K

717K

Ticker HROW
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 27,070,000
Market Cap $885M
Description
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company tha...

Get notified when there are updates to the investment portfolio of Wasatch Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on Wasatch Advisors Inc with notifications on news.